Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by langostaon Jan 25, 2019 3:21pm
64 Views
Post# 29282845

RE:Keep reporting to Stockhouse those off topic posts!

RE:Keep reporting to Stockhouse those off topic posts!Dr Mandel has one month left as interim CEO.

As far as investors are aware the only attempt to conform to item #3 of the terms of Agreement is to place a CEO job listing on the company website for the first 2 weeks of December. application closing date 15 Dec. 2018.

1) Were other methods used in attempting to acquire an external CEO?
We don't know.

2) Is the OSC prepared to extend Dr Mandel's  time as interim CEO?
We don't know.

3) Has the company complied with the other terms of the OSC Agreement?
We don't know.

I have emailed the company more than once listing the terms of Agreement and asking for confirmation regarding the companiy's compliance. 
No answer.

It seems any query that does not pertain to the science but asks  for process on the management end is met with a WALL of silence.

 
Bullboard Posts